STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [8-K] ANAPTYSBIO, INC Reports Material Event

AnaptysBio (NASDAQ: ANAB) moves fiscal year-end to June 30, 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026. The next fiscal year will begin on July 1, 2026.

The company will file a transition Form 10-KT covering the six-month period from January 1, 2026 through June 30, 2026, then begin filing quarterly reports based on the new fiscal year, starting with the quarter ending September 30, 2026.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
New fiscal year-end June 30 Board-approved change on May 18, 2026
Old fiscal year-end December 31 Replaced by June 30 year-end
Transition period length Six months January 1, 2026 through June 30, 2026
Transition report form Form 10-KT For six-month period ending June 30, 2026
First quarter under new year Quarter ending September 30, 2026 First quarterly report under new fiscal year
fiscal year-end financial
"approved a change in the Company’s fiscal year-end from December 31 to June 30"
transition report on Form 10-KT regulatory
"including a transition report on Form 10-KT for the six-month transition period"
A transition report on Form 10-KT is an SEC filing companies submit when they change their fiscal year, providing audited financial statements and management discussion for the shortened transition period between the old and new year-ends. Investors use it like a bridge report: it fills the gap so you can compare results across different reporting calendars, spot one-time adjustments or timing shifts that affect earnings, and judge whether the change reflects operational or accounting shifts that could influence valuation.
Sections 13 or 15(d) of the Securities Exchange Act of 1934 regulatory
"file all required periodic reports under Sections 13 or 15(d) of the Securities Exchange Act of 1934"
periodic reports regulatory
"plans to file all required periodic reports under Sections 13 or 15(d)"
Regularly scheduled documents that a publicly traded company must provide to disclose its financial results, business operations, risks and significant events — like a report card showing revenue, profits, cash flow and key changes over a set period. Investors use these reports to judge a company's health and trends, compare performance over time, and make informed buy, hold or sell decisions; they act as a routine check-up for financial transparency.
Understanding 8-K Material Events →
--12-310001370053false00013700532026-05-182026-05-18

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2026

 

 

ANAPTYSBIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37985

20-3828755

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10770 Wateridge Circle, Suite 210

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 362-6295

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

ANAB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June 30. The Company’s next fiscal year will begin on July 1, 2026. The Company plans to file all required periodic reports under Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including a transition report on Form 10-KT for the six-month transition period of January 1, 2026 through June 30, 2026. The Company then will file quarterly reports based on the new fiscal year beginning with the quarter ending September 30, 2026.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ANAPTYSBIO, INC.

 

 

 

 

Date:

May 21, 2026

By:

/s/ Christopher M. Murphy

 

 

 

Name: Christopher M. Murphy
Title: Chief Financial Officer

 

Source: View Original Filing on SEC EDGAR

FAQ

What change did AnaptysBio (ANAB) announce regarding its fiscal year?

AnaptysBio is changing its fiscal year-end from December 31 to June 30. The board approved this change on May 18, 2026, shifting the company’s annual reporting cycle and aligning future financial reporting with the new June 30 year-end structure.

When will AnaptysBio’s new fiscal year begin after this change?

The company’s next fiscal year will begin on July 1, 2026. This new fiscal year follows a six-month transition period and will establish June 30 as the new fiscal year-end for AnaptysBio’s ongoing financial reporting obligations.

What transition report will AnaptysBio (ANAB) file for 2026?

AnaptysBio plans to file a transition report on Form 10-KT. This report will cover the six-month period from January 1, 2026 through June 30, 2026 under Sections 13 or 15(d) of the Securities Exchange Act of 1934.

How will AnaptysBio’s quarterly reporting schedule change after the fiscal year shift?

AnaptysBio will file quarterly reports based on the new fiscal year. The first quarterly report under this schedule will cover the quarter ending September 30, 2026, reflecting the new July 1 to June 30 fiscal year structure.

Does the AnaptysBio fiscal year change affect its Exchange Act reporting obligations?

The company will continue to file all required periodic reports under the Exchange Act. This includes the special Form 10-KT for the transition period and subsequent quarterly reports aligned with the new June 30 fiscal year-end.

Filing Exhibits & Attachments

1 document

Other Documents